Finance

Lists
Why is MCRB down ५.६०%?
Dive Deeper
MCRB:NASDAQ
Seres Therapeutics Inc
US$ २.५३
-५.६०%
(-०.१५) 1D
अक्टोबर १३, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MCRB...
Open
US$ २.६६
High
US$ २.६६
Low
US$ २.५१
Mkt. cap
२.५२ करोड
Avg. vol.
७१.५६ हजार
Volume
४४.०६ हजार
52-wk high
US$ २९.९८
52-wk low
US$ २.४२
EPS
-US$ २.३३
Beta
०.३१
Shares outstanding
९९.४१ लाख
No. of employees
६६
Open
US$ २.६६
High
US$ २.६६
Low
US$ २.५१
Mkt. cap
२.५२ करोड
Avg. vol.
७१.५६ हजार
Volume
४४.०६ हजार
52-wk high
US$ २९.९८
52-wk low
US$ २.४२
EPS
-US$ २.३३
Beta
०.३१
Shares outstanding
९९.४१ लाख
No. of employees
६६
News stories
From web sources and news partners
About Seres Therapeutics Inc
CEOEric Shaff
Employees६६
Founded२०१०
Headquarters-
Sector-
Websiteserestherapeutics.com
Analyst ratings
Based on 2 analysts giving stock ratings to MCRB in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for MCRB in the last 3 months.
Highest
Current US$ २.५३
US$ २२.०० (+७६९.५७%)
Average
US$ १७.०० (+५७१.९४%)
Lowest
US$ १२.०० (+३७४.३१%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
US$ २२.००
+७६९.६%
08/06/2026
Matthew Keller
H.C. Wainwright
Buy
Reiterated
US$ १२.००
+३७४.३%
08/05/2026
Edward Tenthoff
Piper Sandler
Hold
Maintained
US$ २०.००
+६९०.५%
02/13/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
11/05/2025
Last report
२०२६ अगस्ट ५
Fiscal period
Q2 2026
US$ १.०७ / -US$ २.१८
+१४८.७७%beat
Revenue / Est. (USD)
७.३६ लाख / ३.५८ लाख
+१०५.५९%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
३.५१ लाख
४.३८ लाख
३.५८ लाख
७.३६ लाख
Cost of goods sold
१.३४ करोड
१.२३ करोड
१.३२ करोड
९१.४१ लाख
Cost of revenue
१.३४ करोड
१.२३ करोड
१.३२ करोड
९१.४१ लाख
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
९४.७६ लाख
७५.३९ लाख
८०.७० लाख
७०.६१ लाख
Operating expense
९४.७६ लाख
७५.३९ लाख
८०.७० लाख
७०.६१ लाख
Total operating expenses
२.२८ करोड
१.९८ करोड
२.१३ करोड
१.६२ करोड
Operating income
-२.२५ करोड
-१.९४ करोड
-२.०९ करोड
-१.५५ करोड
Other non operating income
२८.४१ लाख
२३.३१ लाख
६.६९ लाख
६.७३ लाख
EBT including unusual items
८२.०४ लाख
-१.५३ करोड
-१.९९ करोड
४५.८१ लाख
EBT excluding unusual items
-१.९० करोड
-१.६६ करोड
-१.९९ करोड
-१.४६ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
८२.०४ लाख
-१.५३ करोड
-१.९९ करोड
४५.८१ लाख
Net profit margin
२,३३७.३२%
-३,५०१.१४%
-५,५६२.२९%
६२२.४२%
Earnings per share
०.९४
-१.७६
-२.०८
१.०७
Interest and investment income
६.१८ लाख
४.४५ लाख
३.२५ लाख
१.८१ लाख
Interest expense
-
-
-
-
Net interest expenses
६.१८ लाख
४.४५ लाख
३.२५ लाख
१.८१ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२.१४ करोड
-१.८४ करोड
-२.०१ करोड
-१.४८ करोड
Gain or loss from assets sale
-
-१.९२ लाख
-
१.३९ लाख
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू